Form 4 for EWTX Edgewise Therapeutics, Inc.
Accepted 2026-08-14 16:52:31 ET · period of report 2026-08-12 · accession 0001185829-26-000001 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-08-14 16:52 | 2026-08-12 | EWTX | KOCH KEVIN | Pres, CEO, Dir | M - OptEx | $0.00 | +39.8K | 70.5K | +130% | $0 |
| DM | 2026-08-14 16:52 | 2026-08-12 | EWTX | KOCH KEVIN | Pres, CEO, Dir | S - Sale+OE | $43.68 | -18.0K | 52.5K | -26% | -$785.0K |
| DM | 2026-08-14 16:52 | 2026-08-12 | EWTX | KOCH KEVIN | Pres, CEO, Dir | M - OptEx | $0.00 | -39.8K | 65.6K | -38% | $0 |
| DM | 2026-08-14 16:52 | 2026-08-12 | EWTX | KOCH KEVIN | Pres, CEO, Dir | A - Grant | $0.00 | +300.0K | 200.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-12 | M | A | 17,969 | $0.00 | 48,584 | D | — | — | |
| 2 | Common | Common Stock | 2026-08-12 | M | A | 21,875 | $0.00 | 70,459 | D | — | — | |
| 3 | Common | Common Stock | 2026-08-12 | S | D | 8,782 | $43.64 | 61,677 | D | — | — | (F1) Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person (F2) The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $ 43.26 to $44.10, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2026-08-12 | S | D | 8,276 | $43.66 | 53,401 | D | — | — | (F1) Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person (F3) The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.37 to $44.27, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 5 | Common | Common Stock | 2026-08-12 | S | D | 913 | $44.33 | 52,488 | D | — | — | (F1) Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person (F4) The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.33 to $44.33, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 6 | Derivative | Restricted Stock Units | 2026-08-12 | M | D | 17,969 | $0.00 | 35,938 | D | $0.00 · — to 2034-08-12 | 17,969 Common Stock | (F5) Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025. |
| 7 | Derivative | Restricted Stock Units | 2026-08-12 | M | D | 21,875 | $0.00 | 65,625 | D | $0.00 · — to 2035-08-12 | 21,875 Common Stock | (F6) Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026. |
| 8 | Derivative | Restricted Stock Units | 2026-08-12 | A | A | 100,000 | $0.00 | 100,000 | D | $0.00 · — to 2036-08-12 | 100,000 Common Stock | (F7) Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027. |
| 9 | Derivative | Stock Option (Right to Buy) | 2026-08-12 | A | A | 200,000 | $0.00 | 200,000 | D | $43.56 · — to 2036-08-12 | 200,000 Common Stock | (F8) 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date. |